CN110028519A - 山酮素骨架拼接双螺环氧化吲哚化合物及其制备方法及应用 - Google Patents

山酮素骨架拼接双螺环氧化吲哚化合物及其制备方法及应用 Download PDF

Info

Publication number
CN110028519A
CN110028519A CN201910150253.XA CN201910150253A CN110028519A CN 110028519 A CN110028519 A CN 110028519A CN 201910150253 A CN201910150253 A CN 201910150253A CN 110028519 A CN110028519 A CN 110028519A
Authority
CN
China
Prior art keywords
loop coil
double loop
compound
element skeleton
ketone element
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
CN201910150253.XA
Other languages
English (en)
Other versions
CN110028519B (zh
Inventor
刘雄利
左雄
陈爽
周根
周英
袁伟成
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Guizhou University
Original Assignee
Guizhou University
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Guizhou University filed Critical Guizhou University
Priority to CN201910150253.XA priority Critical patent/CN110028519B/zh
Publication of CN110028519A publication Critical patent/CN110028519A/zh
Application granted granted Critical
Publication of CN110028519B publication Critical patent/CN110028519B/zh
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/12—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains three hetero rings
    • C07D491/20—Spiro-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/07—Optical isomers

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)

Abstract

本发明公开了一种山酮素骨架拼接双螺环氧化吲哚化合物，本发明以以各种取代的双功能氧化吲哚‑色酮合成子1、各种取代的3‑烯氧化吲哚2在有机溶剂中，在有机小分子催化剂作用下，进行Michael/Michael环加成反应，获得山酮素骨架拼接双螺环氧化吲哚化合物3，该类化合物包含潜在的生物活性山酮素骨架和螺环氧化吲哚化合物骨架，可以为生物活性筛选提供化合物源，对药物的筛选和制药行业具有重要的应用价值。本发明操作简单易行，原料合成便宜易得，可以在各种有机溶剂中进行，也具有较好的空气稳定性，适用性广，对于各种取代基都有很好的兼容性。且该类骨架化合物对人前列腺(PC‑3),人肺癌细胞(A549)以及人白血病细胞(K562)具有肿瘤生长抑制活性作用。

Description

山酮素骨架拼接双螺环氧化吲哚化合物及其制备方法及应用
技术领域
本发明涉及化学技术和药学技术领域，尤其是一种山酮素骨架拼接双螺环氧化吲哚化合物及其制备方法及应用。
背景技术
根据药物设计的活性骨架拼接和迁越原理，把两个或多个具有生物活性骨架拼接成一个潜在生物活性的多骨架分子在有机化学和医药化学中是极其重要的研究领域。(1)螺六元碳环氧化吲哚广泛存在天然产物和合成药物分子中，吸引了许多化学工作者及医药化学团队的广泛关注，例如，天然产物或活性小分子螺六元碳环氧化吲哚Satavaptan和progesterone receptor agonist II表现明显的生物活性。(2)山酮素骨架也普遍存在天然产物和药物分子中。例如:天然产物分子Ergochrome DD，Diversonol，Desoxydiversonol，Applanatin B和 Isocochlioquinone A共享一个山酮素分子单元，这些化合物在解除病痛、经济发展中起着重大作用。鉴于螺六元碳环氧化吲哚骨架和山酮素骨架具有潜在的生物活性。因此，把螺六元碳环氧化吲哚骨架拼接到山酮素骨架，合成一系列新的潜在多活性官能团的山酮素骨架拼接双螺环氧化吲哚衍生物，可以为生物活性筛选提供化合物源，对药物的筛选和制药行业具有重要的应用价值(如图8所示)。
发明内容
本发明的目的是：提供一种山酮素骨架拼接双螺环氧化吲哚化合物及其制备方法与应用，它是一类重要的医药中间体类似物和药物分子类似物，对药物筛选和制药行业具有重要的应用价值，且其合成方法非常经济简便。
本发明还发现该类化合物在制备防治肿瘤疾病药物中的应用。
本发明是这样实现的：一种山酮素骨架拼接双螺环氧化吲哚化合物，该化合物具有如下通式(Ⅰ)的结构：
式中，R1为甲氧基或氟或氢；R2为甲基或氟或氢；R3为氟或氯或溴或甲基或甲氧基或氢；R4为叔丁基或乙基。
山酮素骨架拼接双螺环氧化吲哚化合物的制备方法，将各种取代的双功能氧化吲哚-色酮合成子1、各种取代的3-烯氧化吲哚2在有机溶剂中，在有机小分子催化剂作用下，进行Michael/Michael环加成反应，获得山酮素骨架拼接双螺环氧化吲哚化合物3。
合成路线举例如下：
其中合成路线中的化合物，其取代基满足R1为甲氧基或氟或氢；R2为甲基或氟或氢；R3为氟或氯或溴或甲基或甲氧基或氢；R4为叔丁基或乙基。
反应机理以3a的合成举例如下：
所述的有机溶剂为乙腈、甲苯、二氯甲烷、或氯仿。
所述的有机小分子碱性催化剂为手性双功能金鸡纳碱衍生的硫脲或芳酰胺、环己基二胺衍生的硫脲或芳酰胺、1,2-二苯基二胺衍生的的硫脲或芳酰胺。
各种取代的双功能氧化吲哚-色酮合成子、各种取代的3-烯氧化吲哚在有机溶剂中的反应温度为-10℃至40℃，反应时间为1至5天。
山酮素骨架拼接双螺环氧化吲哚化合物在制备防治肿瘤疾病药物中的应用。
通过采用上述技术方案，以各种取代的双功能氧化吲哚-色酮合成子1、各种取代的3-烯键氧化吲哚2在有机溶剂中，在有机小分子催化剂作用下，进行 Michael/Michael环加成反应，获得山酮素骨架拼接双螺环氧化吲哚化合物3，该类化合物包含潜在的生物活性山酮素骨架和螺环氧化吲哚化合物骨架，可以为生物活性筛选提供化合物源，对药物的筛选和制药行业具有重要的应用价值。且该骨架化合物对对人前列腺(PC-3),人肺癌细胞(A549)以及人白血病细胞(K562) 具有抑制活性的作用。本发明操作简单易行，原料合成便宜易得，可以在各种有机溶剂中进行，也具有较好的空气稳定性，适用性广，对于各种取代基都有很好的兼容性。
附图说明
附图1及附图2为本发明的实施例的化合物3a’谱图数据；
附图3为化合物3a’液相谱图数据；
附图4及附图5为本发明的实施例的化合物3a谱图数据；
附图6为化合物3a液相谱图数据；
附图7为本发明的实施例的化合物3e和3g单晶图；
附图8为本发明的原理示意图。
具体实施方式
本发明的实施例：在反应管中依次加入39.1mg双功能氧化吲哚-色酮合成子1a(0.10 mmol)，38.9mg 3-烯键氧化吲哚2a(0.15mmol)，5.9mg奎宁衍生的硫脲催化剂C1(10mol ％，0.01mmol)和2.5mL新蒸馏的乙醚溶液，室温中搅拌反应3天，TLC检测基本反应完全，直接上样经柱层析(洗脱剂：V(石油醚)：V(乙酸乙酯)＝4:1)纯化得33.8mg化合物3a’，白色固体，熔点：122.1-123.7℃；33.8mg,产率52％；95％ee,6:1dr,[α]D 20＝120.5(c0.19, CH2Cl2)；The ee was determined by HPLC analysis using a ChiralpakIAcolumn(90/10 hexane/i-PrOH；flow rate:1.0mL/min；λ＝254nm；τmajor＝17.78min；τminor＝11.32min)。核磁共振和高分辨质谱测试等结果如下：1H NMR(CDCl3,400MHz)δ:0.50-0.54(m,3H),1.67(s, 9H),2.46-2.52(m,1H),2.69-2.74(m,1H),2.76(s,3H),3.16-3.22(m,1H),3.31-3.37(m,1H), 3.85-3.94(m,1H),4.13(s,1H),5.89(d,J＝14.0Hz,1H),6.68(d,J＝8.4Hz,1H),6.96-6.70(m, 1H),7.17-7.21(m,2H),7.28-7.38(m,4H),7.76-7.83(m,3H),8.25(d,J＝8.0Hz,1H)；13C NMR (CDCl3,100MHz)δ:13.0,26.9,28.3,31.5,38.9,47.6,54.0,55.9,61.4,80.9,84.7,115.2,115.7, 117.9,120.5,121.8,122.1,125.1,125.8,126.3,127.3,128.0,129.2,129.3,132.5,136.1,139.5, 141.4,149.1,160.1,167.6,170.8,178.8,179.5,192.5；HRMS(ESI-TOF)m/z:Calcd.for C37H34N2NaO9[M+Na]+:673.2157；Found:673.2156.
化合物3a至3x的制备方法同化合物3a’，投料比与化合物3a’相同，可得到化合物3a 至3x，反应产率和dr值,ee值见表1和表2，但需强调的是本发明的化合物不限于表1和表2所表示的内容。
表1为一种山酮素骨架拼接双螺环氧化吲哚化合物的制备方法的化学结构
表2为一种山酮素骨架拼接双螺环氧化吲哚化合物的化学结构
本实施例制备化合物3a:白色固体,熔点：185.4-187.0℃；46.8mg,产率69％；94％ee, >20:1dr,[α]D 20＝128.1(c 0.43,CH2Cl2)；The ee was determined by HPLC analysisusing a Chiralpak IAcolumn(90/10hexane/i-PrOH；flow rate:1.0mL/min；λ＝254nm；τmajor＝12.55 min；τminor＝9.13min)；核磁共振和高分辨质谱测试等结果如下：1H NMR(CDCl3,400MHz)δ: 0.66(s,9H),1.66(s,9H),2.45-2.53(m,1H),2.67-2.73(m,1H),2.74(s.3H),3.87-3.95(m,1H), 4.06(s,1H),5.88(d,J＝14.4Hz,1H),6.68(d,J＝8.0Hz,1H),6.94-6.98(m,1H),7.16-7.21(m, 2H),7.27-7.37(m,4H),7.76-7.82(m,2H),7.85-7.87(m,1H),8.27(d,J＝8.0Hz,1H)；13C NMR (CDCl3,100MHz)δ:26.8,27.0,28.3,31.8,38.9,47.6,54.1,56.9,80.9,82.6,84.7,115.1,115.8, 118.0,120.4,122.0,125.0,125.7,126.9,127.2,128.0,129.0,129.3,132.8,136.1,139.4,141.5, 149.1,160.1,166.2,170.8,178.8,179.5,192.7；HRMS(ESI-TOF)m/z:Calcd.for C39H38N2NaO9 [M+Na]+:701.2470；Found:701.2474.
本实施例制备化合物3b:白色固体,熔点：225.6-227.1℃；63.3mg,产率91％；99％ee, >20:1dr,[α]D 20＝145.8(c 0.33,CH2Cl2)；The ee was determined by HPLC analysisusing a Chiralpak IAcolumn(98/2hexane/i-PrOH；flow rate:1.0mL/min；λ＝254nm；τmajor＝19.79min；τminor＝26.96min)；核磁共振和高分辨质谱测试等结果如下：1H NMR(CDCl3,400MHz)δ: 0.71(s,9H),1.65(s,9H),2.46-2.53(m,1H),2.65-2.71(m,1H),2.73(s,3H),3.86-3.95(m,1H), 4.04(s,1H),5.88(d,J＝14.4Hz,1H),6.69-6.71(m,1H),6.97-7.07(m,2H),7.17-7.21(m,1H), 7.29-7.33(m,2H),7.36-7.41(m,1H),7.63-7.66(m,1H),7.81-7.85(m,2H),8.26-8.30(m,1H)；13C NMR(CDCl3,100MHz)δ:26.8,27.0,28.2,31.8,38.8,47.6,54.3,56.9,80.8,82.9,84.8, 114.8,115.1,115.8(d,JCF＝22.5Hz),117.2(d,JCF＝8.0Hz),117.9,120.5,121.7,122.2,125.1, 127.3,129.1,130.0(d,JCF＝9.1Hz),132.5,136.2,137.6,139.6,149.2,160.0,160.4(d,JCF＝ 243.3Hz),166.1,170.6,178.8,179.0,192.5；HRMS(ESI-TOF)m/z:Calcd.for C39H37FN2NaO9 [M+Na]+:719.2375；Found:719.2378.
本实施例制备化合物3c:白色固体,熔点：112.3-114.1℃；60.5mg,产率87％；>99％ee, >20:1dr,[α]D 20＝112.6(c 0.35,CH2Cl2)；The ee was determined by HPLCanalysis using a Chiralpak IC column(95/5hexane/i-PrOH；flow rate:1.0mL/min；λ＝254nm；τmajor＝18.33min；τminor＝27.93min)；核磁共振和高分辨质谱测试等结果如下：1HNMR(CDCl3,400MHz)δ: 0.71(s,9H),1.66(s,9H),2.43-2.50(m,1H),2.66-2.72(m,1H),2.74(s,3H),3.81-3.90(m,1H), 4.06(s,1H),5.86(d,J＝14.4Hz,1H),6.68-6.71(m,1H),6.96-7.00(m,1H),7.10-7.22(m,3H), 7.28-7.39(m,3H),7.65-7.67(m,1H),7.76-7.82(m,2H)；13C NMR(CDCl3,100MHz)δ:26.2, 26.9,28.2,38.8,47.6,55.3,56.3,80.9,82.9,84.8,115.2,117.7,117.9,120.4,121.6,122.2,122.7, 125.1,126.8(d,JCF＝7.1Hz),127.2,127.6(d,JCF＝10.0Hz),129.0,131.6,132.7,136.2,139.4, 149.0,149.4(d,JCF＝252.0Hz),159.9,166.2,168.2,178.5,178.9,192.4；HRMS(ESI-TOF)m/z: Calcd.forC39H37FN2NaO9[M+Na]+:719.2375；Found:719.2382.
本实施例制备化合物3d:白色固体,熔点：123.2-125.0℃；58.3mg,产率82％；>99％ee, >20:1dr,[α]D 20＝147.6(c 0.33,CH2Cl2)；The ee was determined by HPLCanalysis using a Chiralpak IC column(98/2hexane/i-PrOH；flow rate:1.0mL/min；λ＝254nm；τmajor＝13.97min；τminor＝25.11min)；核磁共振和高分辨质谱测试等结果如下：1HNMR(CDCl3,400MHz)δ: 0.71(s,9H),1.66(s,9H),2.44-2.51(m,1H),2.65-2.72(m,1H),2.73(s,3H),3.84-3.92(m,1H), 4.03(s,1H),5.83(d,J＝14.4Hz,1H),6.69-6.71(m,1H),6.96-7.00(m,1H),7.16-7.21(m,2H), 7.28-7.32(m,2H),7.36-7.40(m,1H),7.77-7.83(m,3H),8.35(d,J＝2.0Hz,1H)；13C NMR (CDCl3,100MHz)δ:26.8,26.9,28.2,31.8,38.8,47.6,53.9,56.7,80.8,82.9,84.8,115.2,116.4, 117.9,120.4,121.6,122.2,125.1,125.7,126.5,127.3,127.9,129.1,132.7,135.1,136.2,139.4, 142.3,149.0,160.0,166.1,170.6,178.9,179.1,192.5；HRMS(ESI-TOF)m/z:Calcd.for C39H37ClN2NaO9[M+Na]+:735.2080；Found:735.2086.
本实施例制备化合物3e:白色固体,熔点：101.1-102.6℃；67.3mg,产率89％；98％ee, >20:1dr,[α]D 20＝110.9(c 0.43,CH2Cl2)；The ee was determined by HPLC analysisusing a Chiralpak IA column(98/2hexane/i-PrOH；flow rate:1.0mL/min；λ＝254nm；τmajor＝16.18min；τminor＝27.37min)；核磁共振和高分辨质谱测试等结果如下：1H NMR(CDCl3,400MHz)δ: 0.72(s,9H),1.66(s,9H),2.46-2.52(m,1H),2.65-2.71(m,1H),2.73(s,3H),3.86-3.94(m,1H), 4.02(s,1H),5.92(d,J＝14.0Hz,1H),6.70(d,J＝8.0Hz,1H),6.97-7.01(m,1H),7.17-7.21(m, 1H),7.30-7.34(m,2H),7.36-7.40(m,1H),7.46-7.49(m,1H),7.81(d,J＝7.6Hz,1H),7.89(d,J ＝8.4Hz,1H),8.00(s,1H),8.18(d,J＝8.4Hz,1H)；13C NMR(CDCl3,100MHz)δ:26.7,27.0, 28.2,31.8,38.8,47.6,54.2,57.3,80.7,83.2,84.7,117.5,117.9,118.5,120.5,121.8,122.2,125.1, 127.3,129.2,130.2,132.2,132.3,136.2,149.4,160.0,166.1,170.7,178.5,192.5；HRMS (ESI-TOF)m/z:Calcd.forC39H37BrN2NaO9[M+Na]+:779.1575；Found:779.1580.
本实施例制备化合物3f:白色固体,熔点：108.4-110.1℃；60.5mg,产率80％；>99％ee, >20:1dr,[α]D 20＝123.6(c 0.19,CH2Cl2)；The ee was determined by HPLCanalysis using a Chiralpak IC column(98/2hexane/i-PrOH；flow rate:1.0mL/min；λ＝254nm；τmajor＝14.12min；τminor＝25.44min)；核磁共振和高分辨质谱测试等结果如下：1HNMR(CDCl3,400MHz)δ: 0.71(s,9H),1.66(s,9H),2.44-2.51(m,1H),2.65-2.71(m,1H),2.73(s,3H),3.84-3.92(m,1H), 4.03(s,1H),5.83(d,J＝14.0Hz,1H),6.70(d,J＝8.4Hz,1H),6.97-7.00(m,1H),7.17-7.20(m, 1H),7.28-7.40(m,4H),7.75-7.82(m,3H),8.50(s,1H)；13C NMR(CDCl3,100MHz)δ:26.8, 26.9,28.2,31.8,38.8,47.6,54.0,56.6,80.7,83.0,84.8,115.2,117.9,119.1,120.4,121.6,122.2, 123.2,125.1,127.1,127.3,128.3,128.7,129.1,132.6,136.2,139.4,142.5,149.0,160.0,166.1, 170.6,178.9,192.5；HRMS(ESI-TOF)m/z:Calcd.for C39H37BrN2NaO9[M+Na]+:779.1575； Found:779.1578.
本实施例制备化合物3g:白色固体,熔点：122.1-123.5℃；42.9mg,产率62％；98％ee, >20:1dr,[α]D 20＝142.0(c 0.25,CH2Cl2)；The ee was determined by HPLC analysisusing a Chiralpak IC column(95/15hexane/i-PrOH；flow rate:1.0mL/min；λ＝254nm；τmajor＝12.77 min；τminor＝19.87min)；核磁共振和高分辨质谱测试等结果如下：1H NMR(CDCl3,400MHz) δ:0.67(s,9H),1.66(s,9H),2.31(s,3H),2.44-2.51(m,1H),2.67-2.71(m,1H),2.73(s,3H), 3.87-3.95(m,1H),4.03(s,1H),5.90(d,J＝14.4Hz,1H),6.69-6.71(m,1H),6.95-6.99(m,1H), 7.12-7.20(m,2H),7.28-7.38(m,3H),7.62(d,J＝1.6Hz,1H),7.80-7.84(m,2H),8.15(d,J＝8.4 Hz,1H)；13C NMR(CDCl3,100MHz)δ:21.4,26.7,27.0,28.3,31.8,38.9,47.6,54.1,57.2,80.8, 82.5,84.5,115.0,115.6,118.0,120.5,121.7,125.0,127.2,127.4,127.8,129.0,129.6,132.7, 135.0,136.1,139.2,139.6,149.3,160.2,166.3,170.7,178.5,179.5,192.8；HRMS(ESI-TOF)m/z: Calcd.for C40H40N2NaO9[M+Na]+:715.2626；Found:715.2628.
本实施例制备化合物3h:白色固体,熔点：95.4-97.1℃；46.7mg,产率66％；>99％ee, >20:1dr,[α]D 20＝90.0(c 0.25,CH2Cl2)；The ee was determined by HPLC analysisusing a Chiralpak IC column(95/5hexane/i-PrOH；flow rate:1.0mL/min；λ＝254nm；τmajor＝13.76min；τminor＝24.10min)；核磁共振和高分辨质谱测试等结果如下：1H NMR(CDCl3,400MHz)δ: 0.69(s,9H),1.62(s,9H),2.46-2.53(m,1H),2.65-2.71(m,1H),2.73(s,3H),3.77(s,3H), 3.88-3.96(m,1H),4.05(s,1H),5.86(d,J＝14.4Hz,1H),6.70-6.72(m,1H),6.86-6.88(m,1H), 6.96-7.00(m,1H),7.16-7.20(m,1H),7.28-7.40(m,3H),7.51(s,1H),7.80-7.86(m,2H),8.19(d, J＝8.8Hz,1H)；13C NMR(CDCl3,100MHz)δ:26.7,26.8,28.2,31.9,38.9,47.6,54.4,55.6,57.0, 80.9,82.6,84.4,111.6,115.2,115.5,116.9,118.0,120.5,121.6,122.0,125.0,127.2,129.0,129.1, 132.8,135.0,136.1,139.6,149.3,157.5,160.2,166.3,170.5,178.7,179.4,192.7；HRMS (ESI-TOF)m/z:Calcd.forC40H40N2NaO10[M+Na]+:731.2575；Found:731.2579.
本实施例制备化合物3i:白色固体,熔点：225.3-226.8℃；51.8mg,产率73％；96％ee, >20:1dr,[α]D 20＝116.8(c 0.37,CH2Cl2)；The ee was determined by HPLC analysisusing a Chiralpak IC column(98/2hexane/i-PrOH；flow rate:1.0mL/min；λ＝254nm；τmajor＝16.09min；τminor＝39.51min)；核磁共振和高分辨质谱测试等结果如下：1H NMR(CDCl3,500MHz)δ: 0.66(s,9H),1.60(s,9H),2.19(s,3H),2.41-2.46(m,1H),2.58-2.64(m,1H),2.67(s,3H), 3.79-3.86(m,1H),3.98(s,1H),5.77(d,J＝14.0Hz,1H),6.54(d,J＝8.5Hz,1H),6.97-7.01(m, 1H),7.13-7.14(m,2H),7.24-7.27(m,2H),7.54(s,1H),7.58-7.61(m,1H),7.78(d,J＝8.0Hz, 1H),8.20-8.23(m,1H)；13C NMR(CDCl3,125MHz)δ:20.4,26.7,26.8,28.1,31.8,38.7,47.4, 54.3,56.7,80.6,82.8,84.6,114.6(d,JCF＝26.3Hz),115.0,155.6(d,JCF＝22.5Hz),116.9,117.0, 117.5,119.9,121.6,124.9,126.7,129.0,129.9(d,JCF＝8.8Hz),131.6,132.4,137.1,139.5,149.1, 158.0,160.2(d,JCF＝242.5Hz),166.0,170.5,178.7,178.9,192.6；HRMS(ESI-TOF)m/z:Calcd. forC40H39FN2NaO9[M+Na]+:733.2532；Found:733.2537.
本实施例制备化合物3j:白色固体,熔点：207.0-208.9℃；50.4mg,产率71％；97％ee, >20:1dr,[α]D 20＝114.1(c 0.27,CH2Cl2)；The ee was determined by HPLC analysisusing a Chiralpak IC column(95/5hexane/i-PrOH；flow rate:1.0mL/min；λ＝254nm；τmajor＝21.84min；τminor＝44.88min)；核磁共振和高分辨质谱测试等结果如下：1H NMR(CDCl3,500MHz)δ: 0.66(s,9H),1.60(s,9H),2.19(s,3H),2.38-2.43(m,1H),2.59-2.64(m,1H),2.68(s,3H), 3.74-3.81(m,1H),4.00(s,1H),5.75(d,J＝14.0Hz,1H),6.54(d,J＝7.5Hz,1H),7.05-7.09(m, 1H),7.11-7.14(m,3H),7.23-7.27(m,2H),7.53(s,1H),7.61(d,J＝7.5Hz,1H),7.72(d,J＝8.0 Hz,1H)；13C NMR(CDCl3,125MHz)δ:20.4,26.1,26.8,28.2,31.7,38.7,47.5,55.2,56.2,80.8, 82.8,84.6,115.1,117.6,119.9,121.5,122.6,124.9,126.7,128.9,131.6,132.7,137.1,139.4, 149.0,149.4(d,JCF＝242.5Hz),158.0,166.2,168.1,178.5,178.8,192.6；HRMS(ESI-TOF)m/z: Calcd.for C40H39FN2NaO9[M+Na]+:733.2532；Found:733.2538.
本实施例制备化合物3k:白色固体,熔点：154.6-156.5℃；55.4mg,产率72％；>25％ee, >20:1dr,[α]D 20＝101.5(c 0.34,CH2Cl2)；The ee was determined by HPLCanalysis using a Chiralpak IC column(98/2hexane/i-PrOH；flow rate:1.0mL/min；λ＝254nm；τmajor＝15.21min；τminor＝37.02min)；核磁共振和高分辨质谱测试等结果如下：1HNMR(CDCl3,500MHz)δ: 0.66(s,9H),1.60(s,9H),2.20(s,3H),2.41-2.46(m,1H),2.58-2.63(m,1H),2.67(s,3H), 3.78-3.85(m,1H),3.96(s,1H),5.82(d,J＝14.0Hz,1H),6.55(d,J＝8.0Hz,1H),7.12-7.15(m, 2H),7.25-7.27(m,2H),7.40-7.42(m,1H),7.55(s,1H),7.84(d,J＝7.5Hz,1H),7.94(d,J＝2.0 Hz,1H),8.12(d,J＝8.5Hz,1H)；13C NMR(CDCl3,125MHz)δ:20.4,26.6,26.8,28.1,31.8, 38.7,47.4,54.1,57.1,80.5,83.1,84.6,115.0,117.3,117.6,118.4,120.0,121.7,125.0,126.7, 129.1,130.1,131.6,132.1,132.2,137.1,139.6,140.5,149.3,158.0,166.0,170.5,178.4,192.6； HRMS(ESI-TOF)m/z:Calcd.for C40H39BrN2NaO9[M+Na]+:793.1731；Found:793.1733.
本实施例制备化合物3l:白色固体,熔点：157.3-158.9℃；53.9mg,产率70％；97％ee, >20:1dr,[α]D 20＝102.6(c 0.27,CH2Cl2)；The ee was determined by HPLC analysisusing a Chiralpak IC column(98/2hexane/i-PrOH；flow rate:1.0mL/min；λ＝254nm；τmajor＝15.77min；τminor＝42.28min)；核磁共振和高分辨质谱测试等结果如下：1H NMR(CDCl3,500MHz)δ: 0.77(s,9H),1.72(s,9H),2.31(s,3H),2.51-2.56(m,1H),2.69-2.74(m,1H),2.79(s,3H), 3.88-3.95(m,1H),4.08(s,1H),5.83(d,J＝14.0Hz,1H),6.66(d,J＝8.5Hz,1H),7.23-7.26(m, 2H),7.34-7.38(m,2H),7.40-7.42(m,1H),7.65(s,1H),7.81-7.84(m,2H),8.56(d,J＝2.0Hz, 1H)；13C NMR(CDCl3,125MHz)δ:20.4,26.7,26.9,28.1,31.9,38.7,47.4,53.9,56.5,80.6,82.8, 84.7,115.1,117.6,118.9,119.9,121.5,123.0,125.0,126.7,127.1,128.2,128.5,128.9,131.6, 132.6,137.1,139.3,142.4,148.9,158.0,166.0,170.5,178.8,178.9,192.6；HRMS(ESI-TOF)m/z: Calcd.for C40H39BrN2NaO9[M+Na]+:793.1731；Found:793.1736.
本实施例制备化合物3m:白色固体,熔点：146.3-148.0℃；51.5mg,产率71％；96％ee, >20:1dr,[α]D 20＝102.2(c 0.18,CH2Cl2)；The ee was determined by HPLC analysisusing a Chiralpak IC column(95/5hexane/i-PrOH；flow rate:1.0mL/min；λ＝254nm；τmajor＝9.35min；τminor＝21.66min)；核磁共振和高分辨质谱测试等结果如下：1H NMR(CDCl3,500MHz)δ: 0.65(s,9H),1.60(s,9H),2.19(s,3H),2.40-2.45(m,1H),2.58-2.63(m,1H),2.68(s,3H), 3.77-3.84(m,1H),3.97(s,1H),5.72(d,J＝14.0Hz,1H),6.55(d,J＝8.5Hz,1H),7.11-7.14(m, 3H),7.23-7.26(m,2H),7.54(s,1H),7.72(d,J＝8.0Hz,1H),7.76(d,J＝8.5Hz,1H),8.29(s, 1H)；13C NMR(CDCl3,125MHz)δ:20.4,26.7,26.9,28.1,31.9,38.7,47.4,53.9,56.6,80.7,82.8, 84.7,115.1,116.2,117.6,119.9,121.5,125.0,125.6,126.5,126.7,127.8,128.9,131.6,132.6, 135.0,137.1,139.3,142.2,148.9,158.0,166.0,170.5,178.8,179.0,192.6；HRMS(ESI-TOF)m/z: Calcd.for C40H39ClN2NaO9[M+Na]+:749.2236；Found:749.2240.
本实施例制备化合物3n:白色固体,熔点：216.3-217.8℃；55.9mg,产率77％；>99％ee, >20:1dr,[α]D 20＝119.6(c 0.24,CH2Cl2)；The ee was determined by HPLCanalysis using a Chiralpak IC column(98/2hexane/i-PrOH；flow rate:1.0mL/min；λ＝254nm；τmajor＝14.72min；τminor＝36.92min)；核磁共振和高分辨质谱测试等结果如下：1H NMR(CDCl3,500MHz)δ: 0.66(s,9H),1.60(s,9H),2.20(s,3H),2.41-2.46(m,1H),2.58-2.64(m,1H),2.67(s,3H), 3.79-3.85(m,1H),3.96(s,1H),5.81(d,J＝14.0Hz,1H),6.55(d,J＝8.5Hz,1H),7.12-7.15(m, 2H),7.24-7.27(m,3H),7.55(s,1H),7.80-7.83(m,2H),8.18(d,J＝8.5Hz,1H)；13C NMR (CDCl3,125MHz)δ:20.4,26.6,26.8,28.1,31.8,38.7,47.4,54.2,57.0,80.5,83.0,84.6,114.9, 116.9,117.6,120.0,121.7,125.0,126.7,127.3,129.0,129.2,129.7,130.7,131.6,132.3,137.1, 140.0,149.3,158.0,166.0,170.5,178.4,178.5,192.6；HRMS(ESI-TOF)m/z:Calcd.for C40H39ClN2NaO9[M+Na]+:749.2236；Found:749.2241.
本实施例制备化合物3o:白色固体,熔点：211.2-212.5℃；59.1mg,产率85％；94％ee, >20:1dr,[α]D 20＝143.8(c 0.29,CH2Cl2)；The ee was determined by HPLC analysisusing a Chiralpak IA column(98/2hexane/i-PrOH；flow rate:1.0mL/min；λ＝254nm；τmajor＝30.30min；τminor＝18.86min)；核磁共振和高分辨质谱测试等结果如下：1H NMR(CDCl3,400MHz)δ: 0.66(s,9H),1.66(s,9H),2.45-2.53(m,1H),2.65-2.70(m,1H),2.74(s,3H),3.86-3.94(m,1H), 4.04(s,1H),5.88(d,J＝14.0Hz,1H),6.65-6.69(m,1H),7.05-7.10(m,1H),7.16-7.22(m,2H), 7.28-7.37(m,3H),7.44-7.47(m,1H),7.77(d,J＝8.0Hz,1H),7.83-7.86(m,1H),8.26(d,J＝8.0 Hz,1H)；13C NMR(CDCl3,100MHz)δ:26.8,27.0,28.2,31.8,38.9,47.6,54.0,57.0,81.1,82.7, 84.8,112.2(d,JCF＝23.3Hz),115.2,115.8,119.7(d,JCF＝7.5Hz),120.9(d,JCF＝6.7Hz),121.6, 123.6(d,JCF＝24.5Hz),125.0,125.8,126.8,127.9,129.0,129.4,132.6,139.4,141.5,149.0, 156.4,158.8(d,JCF＝238.2Hz),170.8,178.8,179.4,192.0；HRMS(ESI-TOF)m/z:Calcd.for C39H37FN2NaO9[M+Na]+:719.2375；Found:719.2379.
本实施例制备化合物3p:白色固体,熔点：138.5-140.1℃；45.0mg,产率62％；97％ee, >20:1dr,[α]D 20＝127.0(c 0.23,CH2Cl2)；The ee was determined by HPLC analysisusing a Chiralpak IC column(95/5hexane/i-PrOH；flow rate:1.0mL/min；λ＝254nm；τmajor＝14.59min；τminor＝25.87min)；核磁共振和高分辨质谱测试等结果如下：1H NMR(CDCl3,500MHz)δ: 0.64(s,9H),1.57(s,9H),2.42-2.47(m,1H),2.58-2.62(m,1H),2.66(s,3H),3.72(s,3H), 3.79-3.89(m,1H),3.98(s,1H),5.80(d,J＝14.5Hz,1H),6.64-6.66(m,1H),6.81-6.83(m,1H), 7.02-7.06(m,1H),7.12-7.15(m,1H),7.24-7.27(m,2H),7.40-7.42(m,1H),7.44(d,J＝2.5Hz, 1H),7.79(d,J＝8.0Hz,1H),8.12(d,J＝9.0Hz,1H)；13CNMR(CDCl3,125MHz)δ:26.7,26.8, 28.1,31.8,38.8,47.5,54.2,55.5,57.0,81.1,82.6,84.4,111.5,112.1(d,JCF＝22.5Hz),115.1, 115.4,116.8,119.6,119.7,121.5,123.5(d,JCF＝25.0Hz),125.0,128.9,129.0,132.6,134.9, 139.5,149.2,156.3,156.6,157.5(d,JCF＝242.5Hz),166.1,170.3,178.6,179.2,192.0；HRMS (ESI-TOF)m/z:Calcd.forC40H39FN2NaO10[M+Na]+:749.2481；Found:749.2485.
本实施例制备化合物3q:白色固体,熔点：201.4-203.2℃；64.3mg,产率90％；98％ee, >20:1dr,[α]D 20＝127.7(c 0.30,CH2Cl2)；The ee was determined by HPLC analysisusing a Chiralpak IC column(95/5hexane/i-PrOH；flow rate:1.0mL/min；λ＝254nm；τmajor＝16.07min；τminor＝33.64min)；核磁共振和高分辨质谱测试等结果如下：1H NMR(CDCl3,400MHz)δ: 0.71(s,9H),1.65(s,9H),2.46-2.53(m,1H),2.62-2.68(m,1H),2.73(s,3H),3.85-3.93(m,1H), 4.02(s,1H),5.87(d,J＝14.0Hz,1H),6.67-6.70(m,1H),7.02-7.12(m,2H),7.17-7.21(m,1H), 7.29-7.33(m,2H),7.45-7.47(m,1H),7.62-7.65(m,1H),7.82-7.84(m,1H),8.25-8.29(m,1H)；13C NMR(CDCl3,100MHz)δ:26.8,27.0,28.2,31.7,38.8,47.6,54.2,57.0,81.0,83.0,84.8, 112.3(d,JCF＝23.0Hz),114.7(d,JCF＝26.1Hz),115.8(d,JCF＝23.0Hz),116.0,119.6,119.7, 121.0,121.7,123.6(d,JCF＝25.1Hz),125.1,129.2,129.8(d,JCF＝9.0Hz),132.3,139.6,149.2, 156.2,157.2(d,JCF＝242.2Hz),160.4(d,JCF＝243.5Hz),166.0,170.5,178.8,178.9,191.8； HRMS(ESI-TOF)m/z:Calcd.for C39H36F2N2NaO9[M+Na]+:737.2281；Found:737.2287.
本实施例制备化合物3r:白色固体,熔点：111.2-113.0℃；62.1mg,产率87％；>99％ee, >20:1dr,[α]D 20＝159.5(c 0.20,CH2Cl2)；The ee was determined by HPLCanalysis using a Chiralpak IC column(95/5hexane/i-PrOH；flow rate:1.0mL/min；λ＝254nm；τmajor＝22.72min；τminor＝32.36min)；核磁共振和高分辨质谱测试等结果如下：1HNMR(CDCl3,500MHz)δ: 0.66(s,9H),1.61(s,9H),2.39-2.44(m,1H),2.59-2.64(m,1H),2.69(s,3H),3.76-3.82(m,1H), 3.99(s,1H),5.81(d,J＝14.5Hz,1H),6.62-6.64(m,1H),7.02-7.10(m,2H),7.12-7.16(m,2H), 7.24-7.27(m,2H),7.39-7.41(m,1H),7.59(d,J＝8.0Hz,1H),7.72(d,J＝8.0Hz,1H)；13C NMR (CDCl3,125MHz)δ:26.1,26.8,28.1,31.5,38.7,47.5,55.0,56.3,81.0,82.9,84.7,112.1(d,JCF＝ 23.8Hz),115.1,117.8(d,JCF＝20.0Hz),119.5,121.5,123.6(d,JCF＝25.0Hz),125.0,126.8, 129.0,132.4,139.3,148.9,149.3(d,JCF＝258.8Hz),156.1,157.5(d,JCF＝241.3Hz),166.0, 168.0,178.3,178.8,191.7；HRMS(ESI-TOF)m/z:Calcd.for C39H36F2N2NaO9[M+Na]+: 737.2281；Found:737.2285.
本实施例制备化合物3s:白色固体,熔点：116.5-122.7℃；64.2mg,产率88％；>99％ee, >20:1dr,[α]D 20＝132.0(c 0.30,CH2Cl2)；The ee was determined by HPLCanalysis using a Chiralpak IC column(98/2hexane/i-PrOH；flow rate:1.0mL/min；λ＝254nm；τmajor＝13.28min；τminor＝24.60min)；核磁共振和高分辨质谱测试等结果如下：1HNMR(CDCl3,400MHz)δ: 0.71(s,9H),1.66(s,9H),2.46-2.53(m,1H),2.63-2.69(m,1H),2.73(s,3H),3.85-3.93(m,1H), 4.00(s,1H),5.91(d,J＝14.0Hz,1H),6.68-6.71(m,1H),7.08-7.13(m,1H),7.17-7.21(m,1H), 7.30-7.34(m,3H),7.45-7.48(m,1H),7.85(d,J＝2.4Hz,1H),7.86-7.89(m,1H),8.23(d,J＝8.8 Hz,1H)；13C NMR(CDCl3,100MHz)δ:26.7,26.9,28.2,31.7,38.8,47.6,54.1,57.3,80.9,83.2, 84.8,112.3(d,JCF＝23.1Hz),115.1,117.1,121.0,121.8,123.6(d,JCF＝25.1Hz),125.1,127.4, 129.3,129.4,129.6,130.9,132.1,139.6,140.1,149.3,156.2,157.6(d,JCF＝242.1Hz),166.0, 170.6,178.5,178.6,191.8；HRMS(ESI-TOF)m/z:Calcd.for C39H36ClFN2NaO9[M+Na]+: 753.1986；Found:753.1991.
本实施例制备化合物3t:白色固体,熔点：121.1-122.6℃；58.4mg,产率80％；98％ee, >20:1dr,[α]D 20＝100.8(c 0.13,CH2Cl2)；The ee was determined by HPLC analysisusing a Chiralpak IC column(95/5hexane/i-PrOH；flow rate:1.0mL/min；λ＝254nm；τmajor＝13.91min；τminor＝32.35min)；核磁共振和高分辨质谱测试等结果如下：1H NMR(CDCl3,400MHz)δ: 0.71(s,9H),1.66(s,9H),2.45-2.51(m,1H),2.62-2.70(m,1H),2.73(s,3H),3.83-3.91(m,1H), 4.02(s,1H),5.83(d,J＝14.4Hz,1H),6.68-6.71(m,1H),7.08-7.13(m,1H),7.17-7.21(m,2H), 7.28-7.32(m,2H),7.44-7.47(m,1H),7.76-7.78(m,1H),7.80(d,J＝8.0Hz,1H),8.34(d,J＝2.0 Hz,1H)；13C NMR(CDCl3,100MHz)δ:26.8,26.9,28.2,31.8,38.8,47.6,53.8,56.8,81.0,83.0, 84.9,112.3(d,JCF＝23.1Hz),115.2,116.4,119.7(d,JCF＝8.2Hz),120.9(d,JCF＝7.3Hz),121.6, 123.6(d,JCF＝25.3Hz),125.1,125.7,126.4,127.9,129.1,132.5,135.2,139.4,142.3,149.0, 156.2,157.6(d,JCF＝241.5Hz),166.0,170.6,178.9,179.0,191.8；HRMS(ESI-TOF)m/z:Calcd. forC39H36ClFN2NaO9[M+Na]+:753.1986；Found:753.1992.
本实施例制备化合物3u:白色固体,熔点：101.1-102.3℃；70.4mg,产率91％；98％ee, 10:1dr,[α]D 20＝99.1(c 0.45,CH2Cl2)；The ee was determined by HPLC analysisusing a Chiralpak IA column(98/2hexane/i-PrOH；flow rate:1.0mL/min；λ＝254nm；τmajor＝13.22min；τminor＝23.73min)；核磁共振和高分辨质谱测试等结果如下：1H NMR(CDCl3,400MHz)δ: 0.71(s,9H),1.66(s,9H),2.46-2.53(m,1H),2.62-2.69(m,1H),2.72(s,3H),3.85-3.93(m,1H), 4.00(s,1H),5.91(d,J＝14.0Hz,1H),6.68-6.72(m,1H),7.08-7.13(m,1H),7.17-7.21(m,1H), 7.30-7.34(m,2H),7.45-7.49(m,2H),7.88-7.90(m,1H),7.98(s,1H),8.17(d,J＝8.8Hz,1H)；13C NMR(CDCl3,100MHz)δ:26.7.,26.9,28.2,31.7,38.8,47.6,54.1,57.3,80.9,83.3,84.8, 112.3(d,JCF＝23.3Hz),115.1,117.5,118.6,119.7(d,JCF＝8.1Hz),121.0(d,JCF＝7.5Hz), 121.1,121.8,123.6(d,JCF＝25.6Hz),125.2,129.3,129.9,130.2,132.1,132.3,139.7,140.6, 149.4,156.2,157.6(d,JCF＝243.5Hz),166.0,170.6,178.4,191.8；HRMS(ESI-TOF)m/z:Calcd. for C39H36BrFN2NaO9[M+Na]+:797.1480；Found:797.1481.
本实施例制备化合物3v:白色固体,熔点：130.3-132.2℃；67.3mg,产率87％；>99％ee, >20:1dr,[α]D 20＝138.0(c 0.25,CH2Cl2)；The ee was determined by HPLCanalysis using a Chiralpak IC column(98/2hexane/i-PrOH；flow rate:1.0mL/min；λ＝254nm；τmajor＝13.96min；τminor＝27.88min)；核磁共振和高分辨质谱测试等结果如下：1HNMR(CDCl3,400MHz)δ: 0.71(s,9H),1.66(s,9H),2.45-2.54(m,1H),2.62-2.68(m,1H),2.73(s,3H),3.83-3.91(m,1H), 4.01(s,1H),5.83(d,J＝14.0Hz,1H),6.69-6.72(m,1H),7.08-7.13(m,1H),7.17-7.21(m,1H), 7.28-7.37(m,3H),7.44-7.47(m,1H),7.74-7.78(m,2H),8.50(d,J＝1.6Hz,1H)；13C NMR (CDCl3,100MHz)δ:26.8,26.9,28.2,38.8,47.6,53.9,56.7,81.0,83.0,84.9,112.3(d,JCF＝23.5 Hz),112.4,115.2,119.1,120.9(d,JCF＝7.1Hz),121.6,123.2,123.7(d,JCF＝25.1Hz),125.1, 126.9,128.2,128.7,129.1,132.5,139.4,142.4,149.0,156.2,157.6(d,JCF＝242.0Hz),166.0, 170.6,178.9,191.8；HRMS(ESI-TOF)m/z:Calcd.for C39H36BrFN2NaO9[M+Na]+:797.1480； Found:797.1484.
本实施例制备化合物3w:白色固体,熔点：134.2-135.8℃；57.8mg,产率81％；94％ee, >20:1dr,[α]D 20＝130.6(c 0.33,CH2Cl2)；The ee was determined by HPLC analysisusing a Chiralpak IAcolumn(98/2hexane/i-PrOH；flow rate:1.0mL/min；λ＝254nm；τmajor＝24.33min；τminor＝15.57min)；核磁共振和高分辨质谱测试等结果如下：1H NMR(CDCl3,400MHz)δ: 0.69(s,9H),1.66(s,9H),2.41-2.48(m,1H),2.64-2.71(m,1H),2.74(s,3H),3.85-3.93(m,1H), 3.97(s,1H),5.84(d,J＝14.4Hz,1H),6.66-6.69(m,1H),6.98-7.03(m,1H),7.05-7.11(m,2H), 7.18-7.22(m,1H),7.33-7.38(m,1H),7.44-7.47(m,1H),7.76-7.80(m,1H),7.80-7.83(m,1H), 8.27(d,J＝8.4Hz,1H)；13C NMR(CDCl3,100MHz)δ:26.8,27.0,28.2,31.6,38.8,47.9,53.9, 56.8,81.1,82.9,85.0,100.0,109.2(d,JCF＝25.1Hz),112.2(d,JCF＝24.7Hz),115.5(d,JCF＝ 23.8Hz),115.8,116.7(d,JCF＝7.1Hz),119.7,120.9(d,JCF＝6.9Hz),123.6(d,JCF＝24.4Hz), 125.8,126.7,127.8,129.4,134.5(d,JCF＝7.5Hz),135.4,141.6,149.0,156.3,156.4,158.8,160.3 (d,JCF＝244.6Hz),166.0,170.7,178.4,179.3,191.8；HRMS(ESI-TOF)m/z:Calcd.for C39H36F2N2NaO9[M+Na]+:737.2281；Found:737.2277.
本实施例制备化合物3x:White solid,熔点：134.6-136.3℃；46.0mg,产率65％；94％ee, >20:1dr,[α]D 20＝95.7(c 0.30,CH2Cl2)；The ee was determined by HPLCanalysis using a Chiralpak IA column(95/5hexane/i-PrOH；flow rate:1.0mL/min；λ＝254nm；τmajor＝30.66min；τminor＝16.44min)；核磁共振和高分辨质谱测试等结果如下：1HNMR(CDCl3,400MHz)δ: 0.69(s,9H),1.65(s,9H),2.43-2.49(m,1H),2.66-2.72(m,1H),2.75(s,3H),3.81(s,3H), 3.86-3.95(m,1H),4.01(s,1H),5.89(d,J＝14.0Hz,1H),6.68(d,J＝8.4Hz,1H),6.80-6.83(m, 1H),6.87(d,J＝2.4Hz,1H),6.95-6.99(m,1H),7.18-7.22(m,1H),7.32-7.38(m,2H),7.70(d,J ＝8.8Hz,1H),7.79-7.82(m,1H),7.87(d,J＝7.2Hz,1H),8.27(d,J＝8.0Hz,1H)；13C NMR (CDCl3,100MHz)δ:26.8,28.3,32.0,38.9,48.0,53.5,54.1,56.0,56.8,80.9,82.6,84.5,108.1, 113.6,115.7,116.2,117.9,120.5,122.0,125.7,126.9,127.2,128.1,129.3,134.1,136.1,149.1, 157.4,160.1,166.2,170.8,178.8,179.6,192.7；HRMS(ESI-TOF)m/z:Calcd.for C40H40N2NaO10[M+Na]+:731.2575；Found:731.2579.
本发明的式(1)化合物具有重要的生物活性，体外对人前列腺(PC-3),人肺癌细胞(A549)以及人白血病细胞(K562)共三株肿瘤细胞的细胞毒性试验表明：此类式(1)所示结构的山酮素骨架拼接双螺环氧化吲哚化合物对肿瘤细胞生长具有抑制作用，有可能发展成为新的防治肿瘤药物。但需强调的是本发明的化合物不限于人前列腺(PC-3),人肺癌细胞(A549)以及人白血病细胞(K562) 表示的细胞毒性。
药理实施例1：化合物3a,3c,3e,3j,3o,3q,3r,3w和3x对PC-3细胞的细胞毒性
PC-3(人前列腺癌)细胞用RPMI-1640培养基培养，培养基中含10％的胎牛血清，100U/mL青霉素及100U/mL的链霉素。细胞以每孔5000个细胞的浓度加入到96孔中，在37℃含5％CO2潮湿空气的培养箱中培养24小时。
细胞存活率的测定用改良MTT法。细胞经过24小时的孵育后，分别将新配的化合物3a,3c,3e,3j,3o,3q,3r,3w和3x的二甲基亚砜溶液以浓度梯度加入到各孔中，使孔中化合物最终浓度分别为5μmol/L,10μmol/L,20μmol/L,40 μmol/L和80μmol/L。48小时后，每孔加入10μL MTT(5mg/mL)的磷酸盐缓冲液，再继续在37℃培养4小时后，离心5分钟除去未转化的MTT，每孔中加入150μL二甲基亚砜。以溶解还原的MTT晶体甲臜(formazan)，用酶标仪在490nm波长测定OD值。其中化合物3a,3c,3e,3j,3o,3q,3r,3w和3x对 PC-3细胞半抑制浓度IC50由spss软件(19版本)分析得到。化合物3a对PC-3肿瘤细胞的IC50为45.09μmol/L；化合物3c对PC-3肿瘤细胞的IC50为25.05μmol/L；化合物3e对PC-3肿瘤细胞的IC50为50.21μmol/L；化合物3j对PC-3肿瘤细胞的IC50为48.90μmol/L；化合物3o对PC-3肿瘤细胞的IC50为40.57μmol/L；化合物3q对PC-3肿瘤细胞的IC50为31.13μmol/L；化合物3r对PC-3肿瘤细胞的IC50为32.44μmol/L；化合物3w对PC-3肿瘤细胞的IC50为24.90μmol/L；化合物3x对PC-3肿瘤细胞的IC50为28.37μmol/L；而阳性对照顺铂对PC-3肿瘤细胞的IC50为21.29μmol/L。
实验结论：PC-3细胞是测试化合物对肿瘤细胞的细胞毒性的有效工具和评价指标。本实验表明此类式(1)所示的山酮素骨架拼接双螺环氧化吲哚化合物对PC-3细胞具有较强的细胞毒性，和肿瘤治疗一线用药顺铂同一数量级，有可能发展成新的具有抗肿瘤作用的药物。
药理实施例2：化合物3a,3c,3e,3o,3q和3r对A549细胞的细胞毒性
A549(人非小细胞肺癌肺癌)用DMEM培养基培养，培养基中含10％的胎牛血清，100U/mL的青霉素和100U/mL链霉素。细胞以每孔4000个细胞的浓度加入到96孔中，在37℃含5％CO2潮湿空气的培养箱中培养24小时。
细胞存活率的测定用改良MTT法。具体方法如药理实施例1。化合物3a对 A549肿瘤细胞的IC50为21.75μmol/L；化合物3c对A549肿瘤细胞的IC50为19.34 μmol/L；化合物3e对A549肿瘤细胞的IC50为49.81μmol/L；化合物3o对A549 肿瘤细胞的IC50为53.78μmol/L；化合物3q对A549肿瘤细胞的IC50为45.24 μmol/L；化合物3r对A549肿瘤细胞的IC50为27.63μmol/L；而阳性对照顺铂对 A549肿瘤细胞的IC50为13.84μmol/L。
实验结论：A549细胞是测试化合物对肿瘤细胞的细胞毒性的有效工具和评价指标。本实验表明此类式(1)所示的山酮素骨架拼接双螺环氧化吲哚化合物对A549细胞具有较强的细胞毒性，和肿瘤治疗一线用药顺铂同一数量级，有可能发展成新的具有抗肿瘤作用的药物。
药理实施例3：化合物3a,3c,3e,3j,3o,3q,3r,3w和3x对K562细胞的细胞毒性
K562(人慢性髓系白血病细胞)用RPMI-1640培养基培养，培养基中含10％的胎牛血清，100U/mL的青霉素和100U/mL链霉素。细胞以每孔5000个细胞的浓度加入到96孔中，在37℃含5％CO2潮湿空气的培养箱中培养24小时。
细胞存活率的测定用改良MTT法。具体方法如药理实施例1。化合物3a对 K562肿瘤细胞的IC50为6.41μmol/L；化合物3c对K562肿瘤细胞的IC50为4.35 μmol/L；化合物3e对K562肿瘤细胞的IC50为8.54μmol/L；化合物3j对K562 肿瘤细胞的IC50为6.12μmol/L；化合物3o对K562肿瘤细胞的IC50为5.32 μmol/L；化合物3q对K562肿瘤细胞的IC50为4.15μmol/L；化合物3r对K562 肿瘤细胞的IC50为4.27μmol/L；化合物3w对K562肿瘤细胞的IC50为5.71μmol/L；化合物3x对K562肿瘤细胞的IC50为5.34μmol/L；而阳性对照顺铂对 K562肿瘤细胞的IC50为17.58μmol/L。
实验结论：K562细胞是测试化合物对肿瘤细胞的细胞毒性的有效工具和评价指标。本实验表明此类式(1)所示的山酮素骨架拼接双螺环氧化吲哚化合物对K562细胞具有较强的细胞毒性，和肿瘤治疗一线用药顺铂同一数量级，有可能发展成新的具有抗肿瘤作用的药物。
从以上药理实施例中我们可以看出这些化合物对这三株肿瘤细胞都显示有一定的细胞毒性。可见这些山酮素骨架拼接双螺环氧化吲哚化合物具有开发成为抗肿瘤药物的潜力，值得继续深入研究下去。

Claims (6)

1.一种山酮素骨架拼接双螺环氧化吲哚化合物，其特征在于：该化合物具有如通式(Ⅰ)所示的结构：
式中，R1为甲氧基、氟或氢；R2为甲基、氟或氢；R3为氟、氯、溴、甲基、甲氧基或氢；R4为叔丁基或乙基。
2.一种如权利要求1所述的山酮素骨架拼接双螺环氧化吲哚化合物的制备方法，其特征在于：将各种取代的双功能氧化吲哚-色酮合成子与各种取代的3-烯氧化吲哚在有机溶剂中，在有机小分子催化剂作用下，进行Michael/Michael环加成反应，获得山酮素骨架拼接双螺环氧化吲哚化合物。
3.根据权利要求2所述的山酮素骨架拼接双螺环氧化吲哚化合物的制备方法，其特征在于：所述的有机溶剂为乙腈、甲苯、二氯甲烷或氯仿。
4.根据权利要求2所述的二山酮素骨架拼接双螺环氧化吲哚化合物的制备方法，其特征在于：所述的有机小分子碱性催化剂为手性双功能金鸡纳碱衍生的硫脲或芳酰胺、环己基二胺衍生的硫脲或芳酰胺、或1,2-二苯基二胺衍生的硫脲或芳酰胺。
5.根据权利要求2所述的二山酮素骨架拼接双螺环氧化吲哚化合物的制备方法，其特征在于：各种取代的双功能氧化吲哚-色酮合成子与各种取代的3-烯氧化吲哚在有机溶剂中的反应温度为-10℃至40℃，反应时间为1至5天。
6.一种如权利要求1所述的山酮素骨架拼接双螺环氧化吲哚化合物在制备防治肿瘤疾病药物中的应用。
CN201910150253.XA 2019-02-28 2019-02-28 山酮素骨架拼接双螺环氧化吲哚化合物及其制备方法及应用 Active CN110028519B (zh)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CN201910150253.XA CN110028519B (zh) 2019-02-28 2019-02-28 山酮素骨架拼接双螺环氧化吲哚化合物及其制备方法及应用

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
CN201910150253.XA CN110028519B (zh) 2019-02-28 2019-02-28 山酮素骨架拼接双螺环氧化吲哚化合物及其制备方法及应用

Publications (2)

Publication Number Publication Date
CN110028519A true CN110028519A (zh) 2019-07-19
CN110028519B CN110028519B (zh) 2022-03-15

Family

ID=67235701

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201910150253.XA Active CN110028519B (zh) 2019-02-28 2019-02-28 山酮素骨架拼接双螺环氧化吲哚化合物及其制备方法及应用

Country Status (1)

Country Link
CN (1) CN110028519B (zh)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN113444101A (zh) * 2021-06-04 2021-09-28 贵州大学 环戊环并色满酮拼接双螺环茚二酮氧化吲哚类化合物及其制备方法及应用

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN107383030A (zh) * 2017-04-10 2017-11-24 贵州大学 姜黄酮拼接3,3’‑吡咯双螺环氧化吲哚化合物及其制备方法及应用

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN107383030A (zh) * 2017-04-10 2017-11-24 贵州大学 姜黄酮拼接3,3’‑吡咯双螺环氧化吲哚化合物及其制备方法及应用

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
NEELAKANDAN VIDHYA LAKSHMI: "An expedient approach for the synthesis of dispiropyrrolidine bisoxindoles,spiropyrrolidine oxindoles and spiroindane-1,3-diones through 1,3-dipolar cycloaddition reactions", 《TETRAHEDRON LETTERS》 *
周英: "通过1，3 － 偶极环加成反应合成3 － 吡咯螺环氧化吲哚的研究进展", 《山地农业生物学报》 *

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN113444101A (zh) * 2021-06-04 2021-09-28 贵州大学 环戊环并色满酮拼接双螺环茚二酮氧化吲哚类化合物及其制备方法及应用

Also Published As

Publication number Publication date
CN110028519B (zh) 2022-03-15

Similar Documents

Publication Publication Date Title
CN104276994B (zh) 3,3′‑双取代氧化吲哚与3‑烯键氧化吲哚拼接衍生物及其制备方法及应用
CN109776556B (zh) 吡唑啉酮山酮素骨架拼接氧化吲哚或苯并呋喃酮类化合物及其制备方法及应用
CN107383030B (zh) 姜黄酮拼接3,3’-吡咯双螺环氧化吲哚化合物及其制备方法及应用
CN112390804B (zh) 环戊烷并色满酮拼接螺环氧化吲哚类化合物及其制备方法及应用
CN111875612B (zh) 色满酮拼接吡咯螺环氧化吲哚骨架与三氟甲基类化合物及其制备方法及应用
CN106008532A (zh) 烷氧基嘧啶拼接3-吡咯螺环氧化吲哚衍生物及其制备方法及应用
CN112047973B (zh) 一种大麻素类化合物，其制备方法、组合物和用途
Zhang et al. Facile synthesis of highly functionalized six-membered heterocycles via PPh3-catalyzed [4+ 2] annulations of activated terminal alkynes and hetero-dienes: scope, mechanism, and application
CN107935910B (zh) 含1′-茚醇拼接3-氧化吲哚类化合物及其制备方法及应用
CN110156796B (zh) 异恶唑拼接3,3’-硫代吡咯啉酮双螺环氧化吲哚化合物及其制备方法及应用
CN103641827A (zh) 中氮茚衍生物及其合成方法和应用
CN110028519A (zh) 山酮素骨架拼接双螺环氧化吲哚化合物及其制备方法及应用
CN109970753B (zh) 山酮素骨架拼接氧化吲哚或苯并呋喃酮类化合物及其制备方法及应用
CN109796471B (zh) 吲哚酮螺环丙烷螺-噻唑酮或螺-四氢噻唑酮类衍生物及其制备方法和应用
CN111892608B (zh) 一种具有光学活性的螺杂环2,3-二氢苯并呋喃类化合物及其应用
CN109705130A (zh) 二氢色原酮骨架拼接多环吡咯螺环氧化吲哚化合物及其制备方法及应用
CN110092793A (zh) 山酮素骨架和异噁唑螺环氧化吲哚拼接衍生物及其制备方法及应用
CN105121419B (zh) Cabazitaxel类抗多药耐药紫杉烷类抗肿瘤化合物及其制备方法
CN111808113B (zh) 六氢山酮素拼接螺环氧化吲哚骨架与酮酯基团类化合物及其制备方法及应用
CN113444101B (zh) 环戊环并色满酮拼接双螺环茚二酮氧化吲哚类化合物及其制备方法及应用
CN102438996B (zh) 点击化学合成的具有分支结构的组蛋白去乙酰酶抑制剂
CN110372714A (zh) 山酮素骨架拼接螺环氧化吲哚类化合物及其制备方法及应用
CN109134478B (zh) 含连续三季碳的硫代吡咯酮拼接双螺环氧化吲哚化合物及其制备方法及应用
CN110684032A (zh) 山酮素异恶唑骨架拼接吡唑啉酮或苯并呋喃酮类化合物及其制备方法及应用
CN110452230A (zh) 一种色原酮吡唑啉酮骨架拼接二氢查尔酮类化合物及其制备方法及应用

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
GR01 Patent grant
GR01 Patent grant